First generation antipsychotics work by blocking dopamine receptors in the brain, specifically the D2 subtype. This reduces dopamine signaling in areas where excessive dopamine activity drives symptoms like hallucinations, delusions, and disordered thinking. The first drug in this class, chlorpromazine, was synthesized in 1951 and became available in France by late 1952, launching a revolution in psychiatric treatment.
Dopamine Blockade at D2 Receptors
Your brain uses dopamine as a chemical messenger between nerve cells. In conditions like schizophrenia, certain brain regions have too much dopamine activity, which produces what clinicians call “positive symptoms”: hallucinations, paranoia, and disorganized thinking. First generation antipsychotics physically attach to D2 receptors on nerve cells and prevent dopamine from binding to them. With dopamine locked out, signaling in those overactive circuits slows down, and psychotic symptoms improve.
The therapeutic sweet spot is surprisingly narrow. Brain imaging studies show that blocking 65% to 80% of D2 receptors produces the best antipsychotic effect. Below 65%, the drug isn’t doing enough to control symptoms. Above 80%, the risk of serious movement-related side effects climbs sharply. This tight window is one of the central challenges with these medications: the dose that controls psychosis sits uncomfortably close to the dose that causes problems.
Four Dopamine Pathways, Four Sets of Effects
Dopamine doesn’t do just one thing in the brain. It operates through four major pathways, and first generation antipsychotics block D2 receptors in all of them. That’s why they treat psychosis effectively but also cause a predictable pattern of side effects.
The mesolimbic pathway connects deep brain structures to areas involved in emotion, motivation, and reward. Overactivity here is the primary driver of hallucinations and delusions. Blocking D2 receptors in this pathway is where the antipsychotic benefit comes from.
The mesocortical pathway runs to the prefrontal cortex, which handles planning, decision-making, and emotional expression. Dopamine activity in this pathway is often already low in schizophrenia, contributing to “negative symptoms” like flat emotion, social withdrawal, and difficulty with motivation. Blocking dopamine here can make those symptoms worse, which is why first generation antipsychotics are considered largely ineffective for this side of the illness.
The nigrostriatal pathway controls voluntary movement. This is the same circuit that degenerates in Parkinson’s disease. When D2 receptors are blocked here, the result is a set of movement problems called extrapyramidal symptoms, which are the most recognizable side effects of these drugs.
The tuberoinfundibular pathway runs from the brain’s hypothalamus to the pituitary gland. Normally, dopamine flowing through this pathway acts as a brake on the release of prolactin, a hormone involved in breast milk production and reproductive function. Block the D2 receptors on prolactin-producing cells and that brake is released. Prolactin levels rise, which can cause breast tenderness, menstrual irregularities, and sexual dysfunction in both men and women.
Movement Side Effects and Why They Happen
Extrapyramidal symptoms are the most distinctive and often most troublesome side effects of first generation antipsychotics. They come in several forms depending on timing and the specific motor circuits affected.
- Dystonia: involuntary muscle contractions that can twist the neck, jaw, or eyes into uncomfortable positions. This tends to appear within hours to days of starting the drug.
- Akathisia: an intense inner restlessness and inability to sit still. People describe it as feeling like they need to pace or constantly shift position.
- Parkinsonism: tremor, stiffness, and slow movement that looks very similar to Parkinson’s disease. It typically develops within weeks of starting treatment.
- Tardive dyskinesia: repetitive, involuntary movements, most often of the mouth, tongue, and jaw. Unlike the others, this appears after months or years of use and can be permanent.
These all trace back to dopamine blockade in the brain’s movement-control centers. The basal ganglia rely on a balance between two motor circuits, one that promotes movement and one that inhibits it. When D2 receptors are blocked, the inhibitory pathway becomes overactive relative to the excitatory one. The result mimics the same imbalance seen in Parkinson’s disease. With chronic use, the brain tries to compensate by becoming hypersensitive to whatever dopamine does get through, which can tip the balance the other direction and produce the involuntary movements of tardive dyskinesia.
Tardive dyskinesia develops at an annualized rate of about 6.5% per year in people taking first generation antipsychotics. Haloperidol, one of the most commonly prescribed drugs in this class, carries a slightly higher rate of around 7.5% per year. For comparison, second generation antipsychotics have an annualized rate of about 2.6%.
Effects Beyond Dopamine
Although D2 blockade is the core mechanism, first generation antipsychotics aren’t perfectly selective. Many of them also bind to receptors for other chemical messengers, and these off-target effects explain several common side effects that have nothing to do with dopamine.
Blocking histamine receptors causes sedation and weight gain, similar to how antihistamine allergy medications make you drowsy. Blocking acetylcholine receptors (the brain’s memory and muscle-signaling chemical) leads to dry mouth, constipation, blurred vision, and urinary retention. Blocking alpha-adrenergic receptors, which help regulate blood vessel tone, causes drops in blood pressure when standing up and compensatory rapid heart rate.
The balance of these off-target effects varies between individual drugs. Low-potency agents like chlorpromazine tend to bind more broadly, producing heavier sedation and more blood pressure effects but somewhat fewer movement problems. High-potency agents like haloperidol bind D2 receptors more tightly and selectively, which means less sedation but a greater risk of extrapyramidal symptoms.
High-Potency vs. Low-Potency Drugs
First generation antipsychotics are often grouped by potency, which refers to how strongly they bind D2 receptors, not how effective they are overall. A high-potency drug like haloperidol achieves the same antipsychotic effect at a much smaller dose than a low-potency drug like chlorpromazine. But because high-potency drugs grip D2 receptors more tightly, they are more likely to push occupancy above that 80% threshold where movement side effects become common.
Low-potency drugs require higher doses and interact with more receptor types along the way. The trade-off is more sedation, more weight gain, and more blood pressure changes, but a somewhat lower rate of the stiffness and tremor associated with high-potency options. In practice, the choice between the two often comes down to which set of side effects is more manageable for a given person.
What These Drugs Treat
First generation antipsychotics were originally developed for schizophrenia, and that remains their primary use. They are effective against positive symptoms: the hallucinations, delusions, and thought disorganization driven by excess dopamine activity. They have also proven useful for acute mania, agitation, and bipolar disorder.
Their limitation is negative symptoms, the emotional flatness, social withdrawal, and cognitive difficulties that many people with schizophrenia experience. Because these symptoms may actually stem from too little dopamine in the prefrontal cortex, blocking dopamine further in that region does not help and can make things worse. This gap in coverage was one of the main motivations for developing second generation antipsychotics, which interact with serotonin receptors in addition to dopamine and may offer modest improvements for negative symptoms.
Despite being older medications, first generation antipsychotics remain widely used worldwide. They are generally less expensive than newer alternatives, and for controlling acute psychosis and positive symptoms, they are comparably effective. The decision between first and second generation options typically hinges on side effect profiles rather than differences in core antipsychotic action.